Etiology of the Stimulant Nature of the Schizophrenias

  • C. C. Pfeiffer
  • R. A. Beck
  • L. Goldstein
  • E. S. Neiss


Because of the lack of homogeneity of the schizophrenias, it is extremely doubtful that a single metabolic defect will be found as the causative factor. An advantageous theory would allow a series of related biochemical findings to be correlated into a common behavioral effect with a variety of final biochemical end-products. In developing this thesis we shall attempt to establish three generalizations: (1) that prolonged stimulation whether it be physical, biochemical, or drug-induced will produce hallucinatory states; (2) that the chronic schizophrenic is in a state of overstimulation; and (3) that alkylation and, more specifically, methylation of the known biogenic amines which occur in the body may result in compounds with greater CNS-stimulant activity and greater lipid solubility. The prolonged stimulation produced by these substituted biogenic amines results in psychosis.


Schizophrenic Patient Biogenic Amine Hippuric Acid Brain Wave Prolonged Stimulation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Friedhoff, A. J., and Van Winkle, E.: Isolation and characterization of a compound from the urine of schizophrenics, Nature 194: 897, 1962.CrossRefGoogle Scholar
  2. 2.
    Brune, G. G., and Himwich, H. E.: Indole metabolites in schizophrenic patients, Arch. Gen. Psychiat. 6: 82, 1962.Google Scholar
  3. 3.
    Perry, T. L.: N-Methylmetanephrine, Science 139: 587–589, 1963.PubMedCrossRefGoogle Scholar
  4. 4.
    Goldstein, L., Murphree, H.B., Sugerman, A.A., Pfeiffer, C.C., and Jenney, E. H.: Electroencephalographic assay of antianxiety drugs, Clin. Pharmacol. Therap. 4: 10–21, 1963.Google Scholar
  5. 5.
    Goldstein, L., and Beck, R.A.: Amplitude analysis of the electroencephalogram. Review of the information obtained with the integrative method, in Pfeiffer, C.C., and Smythies, J.R. (editors): Int. Rev. Neurobiol., Vol. 8, Academic Press, New York, 1965, p. 265.Google Scholar
  6. 6.
    Goldstein, L., Sugerman, A.A., Stolberg, H., Murphree, H.B., and Pfeiffer, C.C.: Electrocerebral activity in schizophrenics and nonpsychotic subjects. Quantitative EEG amplitude analysis, Electroencephalog. Clin. Neurophysiol. 19: 350–361, 1965.CrossRefGoogle Scholar
  7. 7.
    Pfeiffer, C.C., Goldstein, L., Murphree, H.B., andSugerman,A.A.: Time-series, frequency analysis, and electrogenesis of the EEG of normals and psychotics before and after drugs, Am. J. Psychiat. 121: 1147–1155, 1965.PubMedGoogle Scholar
  8. 8.
    Goldman, Douglas: personal communication.Google Scholar
  9. 9.
    Unpublished data (this laboratory).Google Scholar
  10. 10.
    Rodman, F., Griffith, R., and Sparks, C.: Wakefulness in catatonic schizophrenia, Confin. Psychiat. 5: 189–195, 1962.Google Scholar
  11. 11.
    Parfitt, D.N.: Irreversible hypoglycaemic coma in islet-cell adenoma and in schizophrenia, J. Mental Sci. 102: 708, 1956.Google Scholar
  12. 12.
    Goldberg, E. M., and Morrison, S. L.: Schizophrenia and social class, Brit. J. Psychiat. 109: 463, 1963.Google Scholar
  13. 13.
    Smythies, J. R.: Biochemistry of schizophrenia, Postgrad. Med. 39: 26–33, 1963.Google Scholar
  14. 14.
    Persky, H., Grinker, R.R., and Mirsky, I.A.: Excretion of hippuric acid in subjects with free anxiety, J. Clin. Invest. 29: 110, 1950.PubMedCrossRefGoogle Scholar
  15. 15.
    Johannsen, W. J., Friedman, S. H., Feldman, E.I., and Negrete, A.: A re-examination of the hippuric acid—anxiety relationship, Psychosomat. Med., 1962.Google Scholar
  16. 16.
    Murphree, H.B., Dippy, R. H., and Pfeiffer, C.C.: Effects in normal man of a -methyltryptamine and a-ethyltryptamine, Clin. Pharmacol. Therap. 2: 722–726, 1961.Google Scholar
  17. 17.
    Pfeiffer, C.C., Murphree, H.B., Jenney, E.H., Robertson, M.G., Randall, A.H., and Bryan, L.: Hallucinatory effect in man of acetylcholine inhibitors, Fed. Proc. 17: 403, 1958.Google Scholar
  18. 18.
    Pfeiffer, C.C., Murphree, H.B., Jenney, E.H., Robertson, M.G., Randall, A.H., and Bryan, L.: Hallucinatory effect in man of acetylcholine inhibitors, Neurology 9: 249–250, 1958.CrossRefGoogle Scholar
  19. 19.
    Weiss, A.H., Mancall, E.L., Koltes, J.A., White, J.C., and Jackson, L.G.: Dimethylacetamide: A hitherto unrecognized hallucinogenic agent, Science 136: 151–152, 1961.CrossRefGoogle Scholar
  20. 20.
    Abramson, H. A.: Lysergic acid diethylamide (LSD-25): XXIX. The response index as a measure of threshold activity of psychotropic drugs in man, J. Psycho’. 48: 65–78, 1959.CrossRefGoogle Scholar
  21. 21.
    Hoffer, A.: Niacin Therapy in Psychiatry, C.C. Thomas, Springfield.Google Scholar
  22. 22.
    Hoffer, A., and Osmond, H.: Malvaria: A new psychiatric disease, Acta Psychiat. Scand. 40: 171–189, 1964.Google Scholar
  23. 23.
    Ivanova, R.A., Milstein, G.T., Smirnova, L.B., and Fantchenko, N.D.: O vliianii nikotinovoi kisloty na eksperimental’nyi psikhoz, vyzvannyi dietilamidom lizerginovoi kisloty, Zh. Nevropatol. i Psikhiatr. 64: 3, 1964.Google Scholar
  24. 24.
    Tasher, D.C., Abood, L.G., Gibbs, F.A., and Gibbs, E.: Introduction of a new type of psychotropic drug: cyclopentimine, J. Neuropsych. 1: 266, 1960.Google Scholar
  25. 25.
    Pfeiffer, C.C., et al.: Stimulant effect of 2-dimethylaminoethanol-possible precursor of brain acetylcholine, Science 126: 610–611, 1957.PubMedCrossRefGoogle Scholar
  26. 26.
    Murphree, H.B., Jenney, E. H., and Pfeiffer, C.C.: 2-dimethylaminoethanol as a central nervous system stimulant-One aspect of the pharmacology of reserpine, Proc. ARNMD 37: 204–217, 1959.Google Scholar
  27. 27.
    Pfeiffer, C.C.: Present status of deanol as a cerebral stimulant, Psychosomatics 2, 1961.Google Scholar
  28. 28.
    Park, L. C., Baldessarini, R. J., and Kety, S. S.: Methionine effects on chronic schizophrenics, Arch. Gen. Psychiat. 12: 346–351, 1965.CrossRefGoogle Scholar
  29. 29.
    Alexander, F., Curtis, G.C., Sprince, H., and Crosley, A. P.: L-Methionine and L-tryptophan feedings in non-psychotic and schizophrenic patients with and without tranylcypromine, J. Nervous Mental Disease 137: 135–142, 1963.CrossRefGoogle Scholar
  30. 30.
    Brune, G.G., and Himwich, H.E.: Effects of methionine loading on the behavior of schizophrenic patients, J. Nervous Mental Disease 134: 447, 1963.CrossRefGoogle Scholar
  31. 31.
    Quastel, J. H., and Wales, W.T.: Biochemistry and mental disorder, Lancet 2: 301, 1933.Google Scholar
  32. 32.
    Davies, D. R., and Highes, T.P.E.: Faulty detoxication in mental disorder, Lancet 1: 403, 1940.CrossRefGoogle Scholar
  33. 33.
    Gal, E.M.: Lack of lipoic acid activation of acetohiokinase preparations, Nature 198: 1118, 1963.PubMedCrossRefGoogle Scholar
  34. 34.
    Goldstein, L., Pfeiffer, C.C., and Munoz, C.: Quantitative EEG analysis of the stimulant properties of histamine and histamine derivatives, Fed. Proc. 23: 1113, 1964.Google Scholar
  35. 35.
    Brown, D., Tomchick, R., and Axelrod, J.: The distribution and properties of a histaminemethylating enzyme, J. Biol. Chem. 243: 2048, 1959.Google Scholar
  36. 36.
    Salvador, R. A., and Burton, R. M.: Inhibition of the methylation of nicotinamide by chlorpromazine, Biochem. Pharmacol. 14: 1185, 1965.Google Scholar
  37. 37.
    Heyman, J. J.: Nicotinamide metabolism in schizophrenics, drug addicts, and normals. The effect of psychotropic drugs and hormones, Trans. N.Y. Acad. Sci. 26 (3): 354, 1964.PubMedCrossRefGoogle Scholar
  38. 38.
    Kremzner, L.T., and Pfeiffer, C.C.: Identification of substances interfering with the fluoro-metric determination of brain histamine, Biochem. Pharmacol. 15: 197–200, 1966.Google Scholar
  39. 39.
    Kremzner, L.T.: unpublished data.Google Scholar
  40. 40.
    Garrattini, S., and Valzelli, L.: Serotonin, Elsevier Press, p. 377.Google Scholar
  41. 41.
    Caldavere, M., et al.: Polyamines and nucleic acids during development of the chick embryo, Biochem. J. 97: 84, 1965.Google Scholar
  42. 42.
    Heath, R.G., Nesselhof, W., Bishop, M. P., and Byers, L.W.: Behavioral and metabolic changes associated with administration of tetraethylthiuram disulfide (antabuse), Dis. Nerv. Sys. 26: 99, 1965.Google Scholar

Copyright information

© Plenum Press 1967

Authors and Affiliations

  • C. C. Pfeiffer
  • R. A. Beck
  • L. Goldstein
  • E. S. Neiss

There are no affiliations available

Personalised recommendations